Figure 1.
Coronal and transaxial average PET image from 5min to 90 min after IV injection of [ 18 F ]FE-PE2I in rat number 3………………………………..14
Figure 2.
TACs for regional brain uptake after IV injection of [ Molecular imaging is an established tool for the evaluation of DAT in vivo and assessment of the pathophysiology of such diseases.
Among the various DAT imaging radioligands for both single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging, N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β-(4-methylphenyl)nortropane (PE2I) demonstrated a high affinity for DAT and selectivity for DAT over the norepinephrine and serotonin transporter (SERT) (6, 7) . Several animal models and human studies have been performed with 11 C labeled PE2I ( 11 C-PE2I) which showed favorable results (8, 9) . However, there are potential limitations of 11 C-PE2I in quantifying DAT. Firstly, the relatively slow kinetics of 11 C-PE2I requires longer than 90 min imaging acquisitions. Secondly, a radiometabolite of 11 C-PE2I has been found to cross the blood-brain barrier (BBB) of rat brain, and accumulate in the striatum, which limited the kinetic analysis (10, 11) . Also, relatively short half-life is an impediment of 11 C labeled compound for clinical application.
A fluoroethyl analogue of PE2I, [ 18 
Parkinson's disease modeling
Rats were anesthetized with an intraperitoneal injection of a combination of tiletamine/zolazepam (10 mg/kg; Zoletil 50, Virbac, Carros, France), and
Xylazine HCl (10 mg/kg; Rumpen, Bayer Korea, Seoul, Korea) mixture, and placed 4 in a stereotaxic frame. The skull was exposed and a small hole was punctuated with the use of a bone drill. Then, each rat was injected with 20 μg of 6-OHDA (SigmaAldrich, St. Louis, MO, USA) dissolved in 4 μL of 0.05% ascorbic acid solution into the right striatum using Hamilton syringe at a flow rate of 0.5 μL/min (anteroposterior, 0.7 mm; mediolateral, -2.6 mm and dorsoventral, -4.5 mm from the bregma) (20, 21) . Following the injection of 6-OHDA, the Hamilton syringe was sustained in place for 10 min to avoid backflow of 6-OHDA, and the incised scalp was sutured. After surgery, rats recovered from anesthesia in a temperaturecontrolled chamber before returning to the individual cages. 
Drug Treatment

Preparation of [ 18 F]FE-PE2I
PET/CT Imaging
Before imaging, the rats were anesthetized with 5% isoflurane and sustained with 5% isoflurane in a 6:4 mixture of N2/O2. PET/CT imaging was performed in a dedicated small animal PET/CT (NanoPET/CT, Bioscan Inc., 
Image Analysis
Analysis of the PET images was performed using PMOD software version 3.1 (PMOD Technologies Ltd., Zurich, Switzerland). All dynamic PET images were normalized to the standard space via co-registration to MRI rat brain template (20) .
For co-registration, dynamic PET images were first cropped to a manually drawn rectangular region containing the brain of rat. Next, the frames of the first 5 minutes after [
18 F]FE-PE2I injection were averaged to create an early distribution image. This image was co-registered to MRI rat brain template by rigid transformation. This transformation was used to register all dynamic frames of PET images. 8 The volume of interest (VOIs) of the Schiffer template corresponding to the striatum, thalamus, midbrain and cerebellum were used to generate regional timeactivity curves (TACs) on the co-registered images (27 For thalamus and cerebellum, the left and right sides were included in the same VOI.
The correlation of striatal [ 18 F ]FE-PE2I uptake and optical density (OD) of TH-reactive fiber were established by immunohistochemical stain, and average image from 5 min to 90 min were used to measure the ratio of lesioned and unlesioned sides of striatum.
Kinetic Analysis
Kinetic analysis was performed with SRTM method using the cerebellum as a reference region. This is an established method for quantification of DAT due to negligible DAT density in the cerebellum (7) . Prior studies of [ 18 
F]FE-PE2I in human
and primate brain have also reported that BP could be reliably estimated from SRTM method (12, 15) . SRTM method assumes that the level of nonspecific binding is the same in both target and reference regions, and that TAC of target and reference regions can be fit by a 1-tissue compartment model. According to this method, three unknown parameters R1, k2 and BPND are fit using nonlinear regression method (28) .
For investigating the applicability of shorter duration of image acquisition, BPND values with different imaging time from 90 to 30 min were compared.
Tissue Preparation and Immunohistochemistry
After [ 
Statistical Analysis
All statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad Software, Inc., San Diego, CA 
Results
[ 18 F]FE-PE2I for DAT imaging in rat brain
Regional Brain Uptake
Representative PET images and TACs for [ TAC was lower than unlesioned one. Also, midbrain TAC was lower than cerebellar TAC after 24min post injection. BPND was significantly lower in the lesioned striatum than in the unlesioned one or the striatum of normal rats (P < 0.05 according to Dunn's multiple comparison test) (Fig 3) . There was a tendency that BPND of unlesioned striatum from PD rats were lower than that from normal rats, however, it does not reach significance. Midbrain BPND of PD rats was significantly lower than that of normal rats (<0.01 vs 0.25, P < 0.05 according to Kruskal-Wallis test).
Representative coronal and transaxial PET images of BPND parametric map of 
Imaging Time Dependency of Striatal BPND
The values of striatal BPND were relatively stable in relation to the imaging time of 60 min to 90 min (Fig 6) . With a 60-min imaging time, BPND of striatum were approximately 103% of that of a 90-min imaging time. DAT is also known to localize in the midbrain, which contains dopaminergic cell bodies. Reduced DAT on midbrain accompanies the neurodegeneration of midbrain dopaminergic neurons on PD (32, 33) . However, midbrain uptake of previous DAT tracers such as FP-CIT or β-CIT was considered to bind on SERT due to the relatively high affinity to monoamine transporters. Also, pre-treated SSRI significantly reduced those binding on midbrain (34) (35) (36) 
Therapeutic Drug Effects on [ 18 F]FE-PE2I Binding
The study showed that the specific binding of [ 18 F ]FE-PE2I on the striatum was not influenced by the DA receptor agonist and NMDA receptor antagonist, which drugs are conventionally used in treatment PD patients. Also, the results that pretreated SSRI before imaging did not affect the striatal [ primates and human studies, L-DOPA does not affect the DAT binding (17) (18) (19) . In conclusion, L-DOPA effect on DAT binding are unpredictable.
In our study, the dose of L-DOPA/benserazide was chosen as therapeutic range for rat (22 There are potential limitations regarding the methodology of our study. The number of rats we used might be insufficient to assess the effects of therapeutic drugs on striatal BPND. Additional experiment with L-DOPA/benserazide treatment was conducted by paired study design to prove the drug effect deducing the individual difference. Another limitation is that we did not perform sham operation of normal rats in comparing with unilateral 6-OHDA PD rats. The intrastriatal injection is a 25 well-established method (45) and the time interval between the modeling and the imaging acquisition was sufficient to reduce the possible influence. Therefore, omitting the sham operation might reduce the number of animals used as possible.
Also, evaluation of midbrain in rat brain from PET image would be limited due to partial volume effect. Lastly, there is a possibility of isoflurane to change the DAT expression, but not examined in our animal models (46, 47 
